
Heart Failure with Preserved Ejection Fraction (Diastolic CHF) and SGLT-2 Inhibitor Therapy
27/01/2022
0:00
11:32
The double-blind, randomized phase III EMPEROR-Preserved trial showed a benefit of the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF).
Now let us dig a bit more into those headlines.
Mais episódios de "Hospital and Internal Medicine Podcast"



Não percas um episódio de “Hospital and Internal Medicine Podcast” e subscrevê-lo na aplicação GetPodcast.







